Middleton, M., Milhem, M., Aroldi, F., Sacco, J., VanderWalde, A., Baum, S., … Harrington, K. (2021). 506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A538–A538). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.506

Middleton, Mark, Mohammed Milhem, Francesca Aroldi, Joseph Sacco, Ari VanderWalde, Scott Baum, Adel Samson, et al. “506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors.” In Journal for ImmunoTherapy of Cancer, 9:A538–A538. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.506.

Middleton M, Milhem M, Aroldi F, Sacco J, VanderWalde A, Baum S, et al. 506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. In: Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A538–A538.

Middleton, Mark, et al. “506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A538–A538. Crossref, doi:10.1136/jitc-2021-sitc2021.506.

Middleton M, Milhem M, Aroldi F, Sacco J, VanderWalde A, Baum S, Samson A, Chesney J, Niu J, Rhodes T, Bowles T, Emamekhoo H, Tsai K, In G, Beasley G, Chmielowski B, Dalac-Rat S, Kahler K, Muñoz E, Olsson-Brown A, Bommareddy P, Menezes L, Pirzkall A, Coffin R, Harrington K. 506 IGNYTE: an open-label, multicenter, phase 1/2 (Ph 1/2) clinical trial of RP1 ± nivolumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A538–A538.